Laboratory for Molecular Immunology and Inflammation, Department of Rheumatology, Faculty of Medicine and Health Sciences, Ghent University, De Pintelaan 185, 9000, Ghent, Belgium,
Curr Rheumatol Rep. 2015 May;17(5):30. doi: 10.1007/s11926-015-0507-2.
A key role for the IL-23/IL-17 immune axis in spondyloarthritis (SpA) is supported by cumulative evidence from genetic and translational studies and was recently confirmed in clinical trials. Although initially linked to T helper 17 cells, it is now clear that additional unconventional T cell subpopulations respond towards IL-23, including RORγt(+) CD3(+)CD4(-)CD8(-) T cells, TCRγδ17 cells, KIR3DL2(+)CD4(+) T cells and iNKT17 cells. Although these innate-like T cells are present only at low frequencies and often with a specific tissue distribution, it is proposed that they could play a vital function in the development or progression of SpA-related pathology. In this review, we highlight the emerging knowledge on these specialized IL-23 responsive T cells with regard to their relevance in SpA. Finally, we will discuss these findings in light of novel drugs targeting the IL-23/IL-17 axis, currently being tested in SpA patients.
IL-23/IL-17 免疫轴在脊柱关节炎（SpA）中的关键作用得到了遗传和转化研究的累积证据的支持，最近在临床试验中得到了证实。尽管最初与辅助性 T 细胞 17 细胞（Th17 细胞）相关，但现在很明显，其他非常规 T 细胞亚群也对 IL-23 有反应，包括 RORγt（+）CD3（+）CD4（-）CD8（-）T 细胞、TCRγδ17 细胞、KIR3DL2（+）CD4（+）T 细胞和 iNKT17 细胞。虽然这些先天样 T 细胞仅以低频率存在，并且通常具有特定的组织分布，但据推测，它们可能在 SpA 相关病理的发展或进展中发挥重要作用。在这篇综述中，我们强调了这些专门的 IL-23 反应性 T 细胞的新出现的知识，以及它们在 SpA 中的相关性。最后，我们将根据目前正在 SpA 患者中测试的针对 IL-23/IL-17 轴的新型药物，讨论这些发现。
